Navigation Links
PharmaNet Development Group Announces Observational Research Survey
Date:10/11/2010

PRINCETON, N.J., Oct. 11 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries announced today the availability of a new survey on pharmaceutical Observational Research, the fourth in an on-going series. The survey is open to all in the industry with an interest in observational research and can be accessed here through October 31, 2010.  

Jeff Trotter,  Executive Vice President, Phase IV Development, and creator of the survey, remarked, "Pharmaceutical companies are increasingly looking to prospective Observational Research for compiling real world data on post-approval clinical performance, economic value, patient quality-of-life, and product safety. While the scientific community excels at designing and executing controlled clinical trials, there may be less appreciation for the value of observational studies. The goal of the survey is to identify underlying issues in order to move toward more appropriately-designed studies that improve the understanding of product performance among clients, regulators, policymakers, physicians and patients."

Previous surveys have revealed that drug development organizations can benefit from broader cross-functional collaboration and consensus on the strategy for observational research. The latest survey will continue to track evolving trends.

The results of this survey, plus the findings identified in previous surveys, are expected to be released in November.  If you are interested in receiving the findings report or receiving more information on pharmaceutical observational research, please contact aserody@pharmanet.com.  

About PharmaNet Development Group, Inc.PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  Contact: Anne-Marie HessPhone:   (609) 951-6842E-mail:   ahess@pharmanet.com
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
3. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
4. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
5. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
6. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Promising Cystic Fibrosis Compound on Track for Development
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), ... Michigan residents. Naloxone is available ... retail pharmacy, G-3320 Beecher Road. ... and Drug Administration, is intended to block or reverse ... and loss of consciousness. The medication is often carried ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
Breaking Medicine Technology:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... This week ... claims firms in Texas. Founded by Bill Voss, the firm grew quickly and has ... and a half of helping clients get the money they deserve from their insurance ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Earlier this ... authority on the use of health IT to create efficiencies in healthcare information exchange ... held its 2017 Summer Forum which featured keynote addresses by Donald W. ...
(Date:8/23/2017)... ... August 23, 2017 , ... The Stevie® Awards have announced the winners of the Best ... world’s premier business awards competition. , Nominees in the 2017 IBAs were not able to ... system based on the total number of awards won in the IBAs with a Gold ...
(Date:8/23/2017)... ... August 23, 2017 , ... Cirrus Medical Staffing, ... new website, http://www.cirrusmedicalstaffing.com . The new site pairs a robust job search ... professionals who are traveling on short-term assignments to healthcare facilities around the country. ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
Breaking Medicine News(10 mins):